查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853597

內視鏡逆行性造影市場按手術類型、產品類型、應用和最終用戶分類 - 全球預測 2025-2032

Endoscopic Retrograde Cholangiopancreatography Market by Procedure Type, Product, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，內視鏡逆行性造影市場規模將達 37.7 億美元，複合年成長率為 7.86%。

關鍵市場統計數據
基準年2024年 20.5億美元
預計年份：2025年 22.1億美元
預測年份 2032 37.7億美元
複合年成長率（%） 7.86%

全面介紹現代ERCP生態系統，重點闡述其臨床應用範圍、器材類別以及診斷與治療的交叉領域。

內視鏡逆行性造影）仍是肝膽胰疾病診療中診斷影像和治療性介入相結合的基石技術。近年來，該技術已從以診斷為重點的造影發展成為以治療主導的技術，強調括約肌切開術、支架置入術和取石術等標靶干預。隨著臨床實踐向微創內視鏡解決方案轉變，臨床醫生和採購人員都需要清楚地了解技術進步、最佳操作規範以及影響其應用和療效的各種動態。

本執行摘要概述了現代ERCP實踐及其配套器械生態系統的關鍵主題。透過分析內視鏡系統、影像處理輔助設備（如光源和視訊處理器）以及整體配件的進展，本概要描繪了臨床創新的發展軌跡，並兼顧了安全性、培訓和供應鏈韌性等實際考慮。內容涵蓋膽道疾病（包括膽結石、膽漏和膽道狹窄）和胰臟疾病（包括胰臟炎和胰臟腫瘤），反映了ERCP廣泛的臨床應用範圍。

讀者將從中獲得兼顧流程細節和策略遠見的綜合觀點。本書旨在幫助臨床醫生、醫療系統採購負責人和醫療器材創新者做出明智的選擇，使臨床療效與營運實際情況、監管限制以及不斷變化的支付方期望相契合。貫穿全書的過渡性說明重點闡述如何利用科技差異化來減少不利事件、提高病患週轉率並提升醫療品質。

找出正在改變 ERCP 實踐的關鍵變革性轉變，包括增強影像技術、採用單次膽道鏡檢查以及輔助設備創新。

內視鏡逆行性胰膽管攝影術（ERCP）領域正經歷變革時期，主要得益於影像技術、單孔膽道鏡器械以及輔助設備創新技術的同步發展。現代視訊處理器和最佳化光源的運用顯著提升了可視化效果，提高了病灶檢出率和手術精準度；而單孔膽道鏡系統的日益成熟，則拓展了直接可視化能力，從而支持靶向碎石和組織取樣。這些技術主導的變革也得益於輔助設備的改進設計，例如更靈活的導管導引線、精密的括約肌切開刀以及旨在提高輸送性能和減少組織反應的支架平台。

同時，臨床實踐正朝著治療為主的方向發展，內視鏡醫師在臨床適宜的情況下更傾向於微創手術而非外科手術。越來越多的證據支持最佳化手術安全性，進一步強化了這個臨床方向。預防術後胰臟炎的策略，例如使用直腸非類固醇消炎劑和選擇性胰管支架置入術，已成為許多診療路徑的標準組成部分。訓練和模擬也不斷擴展，以幫助操作者熟悉複雜的手術流程和新設備，從而加速安全應用。

供應鏈多元化以及影像和內視鏡平台間互通性的追求，代表著系統性的進一步變革。為了在確保臨床療效的同時精簡庫存，醫院和門診中心越來越重視能夠跨臨床環境提供穩定性能的模組化系統和配件。總而言之，這些轉變正在顯著改變醫療機構優先考慮資本投資、設計臨床工作流程以及與製造商合作開發符合不斷發展的護理標準的解決方案的方式。

評估美國關稅調整至2025年對ERCP器械供應鏈、籌資策略和臨床准入的累積影響

在美國，一系列將於2025年之前實施的關稅政策正對醫療設備供應鏈施加累積壓力，需要製定周密的戰略應對措施。某些零件和成品的進口關稅提高，推高了內視鏡系統、影像處理平台和精密配件的到岸成本。因此，採購團隊必須在有限的資本預算和對先進技術的臨床需求之間取得平衡，並優先考慮臨床影響和整體擁有成本，而不僅僅是單位成本。

製造商和經銷商正採取多樣化的籌資策略來應對挑戰，包括將部分製造、組裝和零件生產轉移到其他地區，以降低對關稅敏感的供應鏈的風險。雖然靠近終端市場可以縮短前置作業時間並減輕跨境關稅的影響，但也可能需要新的資本投資、監管核准和勞動力發展。此外，一些供應商正在調整產品系列，更加重視國內生產的零件和受關稅分類影響較小的替代材料，從而保持淨利率並維持市場進入。

臨床醫生和醫療系統已調整採購行為，深化與供應商在定價模式、批量採購和服務水平協議方面的合作，以應對關稅造成的部分成本波動。同時，人們對現有內視鏡和成像平台的改裝和模組化升級策略越來越感興趣，希望在不進行全面資本更換的情況下延長其使用壽命。最終，到2025年，關稅環境的累積凸顯了臨床、供應鏈和財務相關人員之間開展跨職能規劃的必要性，以在控制成本波動的同時，確保臨床創新成果的持續應用。

基於深度細分的洞察揭示了手術類型、產品架構、臨床應用和醫療環境如何決定ERCP的採用和採購。

深入的市場區隔揭示了手術決策、產品架構、臨床適應症和醫療環境如何相互交織，共同塑造器材的使用和創新路徑。基於手術類型，市場研究分為診斷和治療兩大類。診斷方面，我們進一步探討了造影和造影；治療方面，我們進一步探討了括約肌切開術、支架置入術和取石術。區分這些手術至關重要，因為診斷流程優先考慮影像保真度和易用性，而治療流程則需要耐用的配件、可靠的支架輸送系統以及針對取石和組織操作最佳化的工具。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 增加一次性十二指腸鏡的使用，以降低交叉感染風險
  • 先進數位膽道鏡平台在標靶膽道介入治療的應用日益廣泛
  • 人工智慧驅動的影像分析技術在ERCP術中即時病灶檢測的進展
  • 開發一種非侵入性導管導引線系統，以提高複雜解剖結構插管的成功率
  • 混合式 ERCP超音波檢查的需求日益成長，這種檢查可以將診斷和治療結合在一次檢查中完成。
  • 擴充包含擴增實境的訓練模擬模組，以提升ERCP技能

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依手術類型分類的內視鏡逆行性造影市場

  • 診斷
    • 造影
    • 胰臟造影
  • 治療
    • 括約肌切開術
    • 支架置入
    • 石材開採

9. 內視鏡逆行性造影市場（依產品分類）

  • 配件
  • 內視鏡系統
  • 影像系統
    • 光源
    • 視訊處理器

第10章 內視鏡逆行性造影市場（依應用領域分類）

  • 膽道疾病
    • 膽結石
    • 洩漏
    • 收縮
  • 胰臟疾病
    • 胰臟炎
    • 瘤

第11章 內視鏡逆行性造影市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

12. 內視鏡逆行性造影市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 內視鏡逆行性造影市場（依組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國內鏡逆行造影市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Olympus Corporation
    • Boston Scientific Corporation
    • Medtronic plc
    • Fujifilm Holdings Corporation
    • HOYA Corporation
    • KARL STORZ SE & Co. KG
    • Cook Medical LLC
    • CONMED Corporation
    • Ambu A/S
    • Stryker Corporation
Product Code: MRR-5A2C6AA6657B

The Endoscopic Retrograde Cholangiopancreatography Market is projected to grow by USD 3.77 billion at a CAGR of 7.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.05 billion
Estimated Year [2025] USD 2.21 billion
Forecast Year [2032] USD 3.77 billion
CAGR (%) 7.86%

Comprehensive introduction to the contemporary ERCP ecosystem highlighting clinical scope, device categories, and the intersection of diagnostic and therapeutic practice

Endoscopic retrograde cholangiopancreatography remains a cornerstone procedure at the interface of diagnostic imaging and therapeutic intervention within hepatobiliary and pancreatic care. Over recent years, the procedure has evolved from principally diagnostic cholangiography and pancreatography into a therapy-driven modality emphasizing targeted interventions such as sphincterotomy, stent placement, and stone extraction. As clinical practice pivots toward minimally invasive endoscopic solutions, practitioners and procurement professionals alike require a clear synthesis of technological advances, procedural best practices, and the shifting dynamics that influence adoption and outcomes.

This executive summary consolidates essential themes that define contemporary ERCP practice and the device ecosystem that supports it. By examining advances in endoscope systems, imaging adjuncts such as light sources and video processors, and the full complement of accessories, the analysis maps the trajectory of clinical innovation alongside practical considerations of safety, training, and supply chain resilience. Importantly, the content addresses both biliary system disorders including gallstones, leaks, and strictures, and pancreatic system disorders such as pancreatitis and tumors, reflecting the broad clinical footprint of ERCP.

Readers will find an integrated perspective that balances procedural detail with strategic foresight. The aim is to enable clinicians, health-system procurement leaders, and device innovators to make informed choices that align clinical efficacy with operational realities, regulatory constraints, and evolving payer expectations. Transitional commentary throughout this document highlights opportunities to reduce adverse events, improve patient throughput, and leverage technological differentiation to advance care quality.

Identifying the major transformative shifts altering ERCP practice including imaging enhancements, single-operator cholangioscopy adoption, and accessory innovation

The ERCP landscape is undergoing transformative shifts driven by parallel advances in imaging, single-operator cholangioscopy, and accessory innovation. Enhanced visualization provided by modern video processors and optimized light sources has improved lesion detection and procedural precision, while the maturation of single-operator cholangioscopy systems has expanded direct-visualization capabilities that support targeted lithotripsy and tissue acquisition. These technology-led changes are complemented by improvements in accessory design including more flexible guidewires, refined sphincterotomes, and stent platforms engineered for deliverability and reduced tissue reaction.

Concurrently, clinical practice has trended toward therapeutic-first approaches in many indications, with endoscopists increasingly favoring minimally invasive interventions over surgical alternatives when clinically appropriate. This clinical pivot is reinforced by growing evidence for procedural safety optimization, with prophylactic strategies against post-procedure pancreatitis such as rectal nonsteroidal anti-inflammatory drug use and selective pancreatic stenting becoming standard components of many care pathways. Training and simulation have also expanded, supporting operator proficiency in complex maneuvers and new device utilization, thereby accelerating safe adoption.

Supply chain diversification and the pursuit of interoperability across imaging and endoscope platforms represent additional systemic shifts. As hospitals and ambulatory centers seek to streamline inventories while ensuring clinical efficacy, there is greater emphasis on modular systems and accessories that deliver consistent performance across a range of clinical settings. Taken together, these shifts are reshaping how institutions prioritize capital investments, design clinical workflows, and partner with manufacturers to co-develop solutions that align with evolving standards of care.

Assessing the cumulative impact of tariff shifts in the United States through 2025 on ERCP device supply chains, procurement strategies, and clinical access

In the United States, tariff policies enacted through 2025 have exerted cumulative pressures on the medical device supply chain that warrant careful strategic response. Increased import duties on selected components and finished devices have elevated landed costs for endoscope systems, imaging platforms, and high-precision accessories. As a result, procurement teams must reconcile the clinical imperative of advanced technology adoption with constrained capital budgets, prompting prioritization exercises that emphasize clinical impact and total cost of ownership rather than unit price alone.

Manufacturers and distributors have responded with diversified sourcing strategies, relocating portions of manufacturing, assembly, or component production to mitigate exposure to tariff-sensitive supply lines. This re-shoring and near-shoring activity has introduced both opportunities and complexities: while proximity to end markets can shorten lead times and reduce exposure to cross-border duties, it may also necessitate new capital investments, regulatory approvals, and workforce training. Moreover, some suppliers have shifted product portfolios to emphasize domestically manufactured components or alternative materials that are less affected by tariff classifications, enabling continued market access while preserving margins.

Clinicians and health systems have adapted procurement behavior by increasing collaboration with vendors on pricing models, bundled purchasing, and service-level agreements that absorb parts of tariff-driven cost variability. In parallel, there has been greater interest in retrofit and modular upgrade strategies for existing endoscope and imaging platforms to extend usable lifecycles without full capital replacement. Ultimately, the cumulative tariff environment through 2025 has reinforced the imperative for cross-functional planning among clinical, supply chain, and finance stakeholders to preserve access to clinical innovations while managing cost volatility.

Deep segmentation-driven insights revealing how procedure type, product architecture, clinical application, and care setting jointly determine ERCP adoption and procurement

Insightful segmentation clarifies how procedural decision-making, product architecture, clinical indication, and care setting intersect to shape device utilization and innovation pathways. Based on Procedure Type, market is studied across Diagnostic and Therapeutic; the Diagnostic is further studied across Cholangiography and Pancreatography while the Therapeutic is further studied across Sphincterotomy, Stent Placement, and Stone Extraction. These procedural distinctions matter because diagnostic workflows prioritize imaging fidelity and maneuverability, whereas therapeutic workflows demand durable accessories, reliable stent delivery systems, and tools optimized for extraction and tissue manipulation.

Based on Product, market is studied across Accessories, Endoscope Systems, and Imaging Systems; the Imaging Systems is further studied across Light Sources and Video Processors. Product segmentation highlights the layered nature of procurements where core capital equipment investments in endoscope systems and imaging platforms are paired with high-turnover accessory portfolios that influence recurring spend and clinical throughput. Accessories often drive procedure-level performance metrics, and their compatibility with legacy systems is a common determinant of purchasing decisions.

Based on Application, market is studied across Biliary System Disorders and Pancreatic System Disorders; the Biliary System Disorders is further studied across Gallstones, Leaks, and Strictures while the Pancreatic System Disorders is further studied across Pancreatitis and Tumors. Application-based segmentation underscores the clinical drivers of device selection, as the management of gallstones or strictures may prioritize lithotripsy-capable platforms and stent technology, while tumor-related indications often require enhanced imaging, biopsy capability, and multidisciplinary coordination. Finally, based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. End-user segmentation reflects variability in capital budgets, case complexity, and throughput expectations, with ambulatory centers focusing on efficiency and cost control, hospitals balancing high-acuity caseloads with teaching and research imperatives, and specialty clinics emphasizing niche expertise and longitudinal patient management.

Key regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape ERCP deployment and supply chain strategies

Regional dynamics influence technology adoption, clinical practice patterns, and supply chain configurations in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among health systems and a strong emphasis on value-based care are driving demand for devices that demonstrate procedural efficiency and measurable outcomes, while centers of excellence in tertiary hospitals continue to serve as early adopters of advanced cholangioscopy and lithotripsy technologies. Regional payer structures also influence procurement timing and the appetite for bundled purchasing or capital leasing arrangements that optimize cash flow.

Within Europe, the Middle East & Africa, heterogeneity in regulatory regimes and healthcare funding models creates a mosaic of adoption rates. Some countries with centralized procurement favor standardized platforms that can be deployed broadly, whereas others prioritize innovation within leading academic centers. In several EMEA markets, efforts to expand minimally invasive care pathways are stimulating interest in training programs and partnerships that accelerate operator skill acquisition, thus creating a pipeline for broader device uptake.

Asia-Pacific presents a highly dynamic environment where rapid clinical capacity expansion and large patient volumes have spurred investment in both capital equipment and workforce development. High-volume centers in major metropolitan areas often pioneer new procedural workflows and leverage scale to negotiate favorable procurement terms. Simultaneously, regional manufacturing hubs and component suppliers have become important nodes in the global supply chain, affecting availability and pricing of accessories and replacement parts. Across all regions, cross-border collaboration, regulatory harmonization efforts, and clinical evidence generation continue to shape how devices are evaluated and adopted in practice.

Company-level dynamics highlighting innovation in endoscopes, imaging platforms, accessory design, and strategic partnerships that accelerate clinical adoption

A focused set of manufacturers, clinical innovators, and technology integrators are driving the current evolution of ERCP tools and supporting ecosystems. Leading endoscope and imaging platform providers have invested in higher-resolution video processors and optimized light sources to improve diagnostic clarity and procedural confidence. Concurrently, accessory specialists have concentrated on developing more deliverable stent systems, low-trauma sphincterotomes, and efficient stone extraction tools that reduce procedure time and complication risk. These product-level innovations are frequently paired with enhanced training programs, service offerings, and data-driven support to facilitate adoption.

Strategic partnerships between device firms and clinical centers have become more common, accelerating real-world evidence collection and enabling iterative product refinement. In addition, manufacturers are increasingly offering bundled service and maintenance programs that reduce total lifecycle costs and provide predictable budgeting for end users. Distribution partners and system integrators play a pivotal role in ensuring compatibility between endoscope systems and third-party imaging modules, and they often contribute to after-sales training and support which are critical for complex therapeutic procedures.

Finally, newer entrants and niche innovators focusing on cholangioscopy-guided lithotripsy, biodegradable stents, and single-use accessory concepts are reshaping competitive dynamics. Their presence encourages incumbents to improve product differentiation and to expand clinical studies that demonstrate tangible improvements in safety or efficiency. Collectively, these company-level trends underscore a market where clinical credibility, service excellence, and interoperability are central to commercial success.

Actionable recommendations for industry leaders to align product design, clinical evidence, and supply chain resilience to accelerate adoption and deliver measurable value

Industry leaders should adopt a multi-pronged strategy that aligns product innovation, clinical evidence generation, and supply chain resilience to sustain competitive advantage and improve patient outcomes. First, prioritizing modular and interoperable system architectures will allow institutions to upgrade imaging or processing components without replacing entire endoscope platforms, thereby reducing capital barriers to adopting advanced visualization. Investing in accessories that are backward-compatible with legacy systems can also expand addressable markets and ease procurement decisions.

Second, companies and health systems should co-invest in robust clinical evidence programs that measure not only immediate procedural outcomes but also longitudinal metrics such as reintervention rates, health-economic impact, and patient-reported outcomes. These data will be critical to justify adoption in value-conscious purchasing environments and to support payer engagement. Third, developing tariff-mitigation strategies such as diversified sourcing, near-shoring critical component production, and transparent pricing models will reduce exposure to policy-driven cost variability and improve supply predictability.

Fourth, expanding operator training and simulation offerings will both speed safe adoption of advanced techniques and reduce complication rates that can erode confidence in new technologies. Finally, adopting outcome-based contracting and bundled-service models can align incentives between manufacturers, providers, and payers, promoting broader access to innovations while sharing the financial risk of new technology deployment.

Robust mixed-methods research methodology combining expert interviews, clinical literature review, and practical scenario mapping to validate ERCP trends and implications

The analysis underpinning this executive summary synthesizes a structured research approach that blends primary stakeholder engagement with comprehensive secondary review of clinical and regulatory sources. Primary research included interviews with practicing endoscopists, hospital procurement leaders, specialty clinic administrators, and device OEM representatives to capture current adoption patterns, unmet needs, and procurement decision drivers. These conversations were augmented by procedural observations and input from clinical educators to validate assumptions about training requirements and workflow integration.

Secondary research incorporated peer-reviewed clinical literature, regulatory filings, device labeling, and publicly available procedural guidelines to ensure technical accuracy and alignment with contemporary clinical practice. Where appropriate, registries and procedural outcome datasets were canvassed to corroborate trends in complication mitigation strategies and device utilization. Attention was given to recent advances in imaging technology, single-operator cholangioscopy modalities, and accessory-driven innovations to reflect the most relevant developments influencing clinical decision-making.

Analytical methods included thematic synthesis of qualitative inputs and triangulation across sources to identify consistent patterns and strategic implications. The methodology also entailed scenario mapping to assess the operational impacts of supply chain disruptions and tariff-related cost shifts, enabling practical recommendations that are responsive to both clinical and commercial realities.

Conclusive synthesis of ERCP strategic imperatives emphasizing technology, clinical evidence, and collaborative approaches to advance care and manage cost pressures

In sum, the ERCP landscape is characterized by rapid technological refinement, procedural shifts toward therapeutic-first care, and evolving procurement dynamics shaped by regional policy and tariff influences. Improved imaging, the rise of single-operator cholangioscopy, and accessory innovation are collectively enhancing the efficacy and scope of endoscopic interventions for biliary and pancreatic disorders. These clinical and technological drivers are occurring alongside heightened attention to procedural safety, operator training, and interoperable system architectures that support sustainable adoption.

Going forward, stakeholders who successfully integrate clinical evidence, flexible product design, and supply chain strategies will be best positioned to deliver improved patient outcomes while managing cost and access pressures. Collaboration among device manufacturers, clinical centers, and payers will be essential to translate incremental innovations into measurable clinical and economic value. By focusing on interoperability, lifecycle cost management, and outcome-oriented contracting, organizations can navigate current headwinds and seize opportunities to expand the role of ERCP in minimally invasive hepatobiliary and pancreatic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of single-use disposable duodenoscopes to mitigate cross-contamination risks
  • 5.2. Increased utilization of advanced digital cholangioscopy platforms for targeted biliary interventions
  • 5.3. Advancements in artificial intelligence driven image analysis for real-time lesion detection during ERCP
  • 5.4. Development of atraumatic guidewire systems to improve cannulation success rates in complex anatomy
  • 5.5. Rising demand for hybrid ERCP endoscopic ultrasound procedures to combine diagnosis and therapy in single session
  • 5.6. Expansion of training simulation modules incorporating augmented reality to expedite ERCP proficiency acquisition

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Retrograde Cholangiopancreatography Market, by Procedure Type

  • 8.1. Diagnostic
    • 8.1.1. Cholangiography
    • 8.1.2. Pancreatography
  • 8.2. Therapeutic
    • 8.2.1. Sphincterotomy
    • 8.2.2. Stent Placement
    • 8.2.3. Stone Extraction

9. Endoscopic Retrograde Cholangiopancreatography Market, by Product

  • 9.1. Accessories
  • 9.2. Endoscope Systems
  • 9.3. Imaging Systems
    • 9.3.1. Light Sources
    • 9.3.2. Video Processors

10. Endoscopic Retrograde Cholangiopancreatography Market, by Application

  • 10.1. Biliary System Disorders
    • 10.1.1. Gallstones
    • 10.1.2. Leaks
    • 10.1.3. Strictures
  • 10.2. Pancreatic System Disorders
    • 10.2.1. Pancreatitis
    • 10.2.2. Tumors

11. Endoscopic Retrograde Cholangiopancreatography Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Endoscopic Retrograde Cholangiopancreatography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endoscopic Retrograde Cholangiopancreatography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endoscopic Retrograde Cholangiopancreatography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Olympus Corporation
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Fujifilm Holdings Corporation
    • 15.3.5. HOYA Corporation
    • 15.3.6. KARL STORZ SE & Co. KG
    • 15.3.7. Cook Medical LLC
    • 15.3.8. CONMED Corporation
    • 15.3.9. Ambu A/S
    • 15.3.10. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET S